Vicore to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Stockholm, February 10, 2025 – Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Ahmed Mousa, Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.
- Presentation Date and Time: Wednesday, February 12, 2025, at 8:00 AM ET/2:00 PM CET
- Presenter: Ahmed Mousa, CEO
- Webcast: https://wsw.com/webcast/oppenheimer39/vico/2791144
Interested parties may also access the webcast replay on Vicore’s website for 90 days following the conclusion of the event.
For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com